The objective of this survey was to understand the safety and efficacy of PAXIL tablets ("PAXIL", hereinafter) when it was started at 20 mg/day in subjects with depression or in a depressed state.
Study Type
OBSERVATIONAL
Enrollment
1,483
Incidence of adverse events
Incidence of adverse events in Japanese subjects treated with paroxetine tablet based on prescribing information under the conditions of general clinical practice
Time frame: 12 weeks
Efficacy evaluation based on overall improvement
The investigator compared the general condition over 1 week before each clinical visit with that over 1 week before the start of treatment with PAXIL.
Time frame: 12 weeks
Efficacy evaluation based on severity by symptoms
At every clinical visit, the investigator rated each of the specified symptoms including depressed mood, loss of interests/concerns, anxiety, lack of motivation, physical symptoms, and sleep disorders.
Time frame: 12 weeks
Efficacy evaluation based on Beck Depression Inventory- Second Edition (BDI-II)
The investigator asked each subject to fill out the self-administered form of BDI-II at every clinical visit (recommended clinical visit schedule: 1, 2, 4, 8, and 12 weeks after the start of treatment).
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.